

Arfenya E Karamova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9003000/publications.pdf>

Version: 2024-02-01

21
papers

48
citations

1937685

4
h-index

1872680

6
g-index

21
all docs

21
docs citations

21
times ranked

37
citing authors

#	ARTICLE	IF	CITATIONS
1	Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. <i>Journal of Personalized Medicine</i> , 2021, 11, 20.	2.5	11
2	Epidemiology and Providing of Healthcare for Patients with Inherited Epidermolysis Bullosa in the Russian Federation. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 420-430.	0.6	7
3	Allogeneic fibroblast cell therapy in the treatment of recessive dystrophic epidermolysis bullosa. <i>Wound Medicine</i> , 2018, 21, 8-11.	2.7	6
4	Congenital epidermolysis bullosa: modern methods of diagnosis and therapy. Prospects for regenerative medicine. <i>Vestnik Dermatologii I Venerologii</i> , 2020, 96, 10-17.	0.6	5
5	The effect of apremilast therapy on skin cytokine levels in patients with psoriasis. <i>Russian Open Medical Journal</i> , 2020, 9, .	0.3	3
6	Modern concepts of the mycosis fungoides pathogenesis. <i>Oncogematologiya</i> , 2018, 13, 39-46.	0.3	3
7	Cytokine Levels of Skin Lesions in Moderate and Severe Psoriasis as Predictors for the Type 4 Fosphodiesterase Inhibitor (Apremilast) Therapy Effectivness. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020, 75, 500-507.	0.6	3
8	Effect of PUVA and NB-UVB Therapy on the Skin Cytokine Profile in Patients with Mycosis Fungoides. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	1.3	2
9	Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial. <i>Vestnik Dermatologii I Venerologii</i> , 2022, 98, 42-52.	0.6	2
10	EFFICACY OF SELECTIVE PDE-4 INHIBITOR IN PATIENTS WITH PSORIASIS: CLINICAL OBSERVATIONS. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018, 73, 81-87.	0.6	1
11	A CASE REPORT OF AGGRESSIVE SQUAMOUS CELL CARCINOMA IN PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA. <i>Voprosy Onkologii</i> , 2020, 66, 556-562.	0.2	1
12	Genetic markers for psoriatic arthritis in patients with psoriasis. Part I: non-HLA genes. <i>Vestnik Dermatologii I Venerologii</i> , 2021, 97, 33-47.	0.6	1
13	Revisiting the question of cutaneous vasculitis classification. <i>Vestnik Dermatologii I Venerologii</i> , 2021, 97, 48-59.	0.6	1
14	Topical treatment of inherited epidermolysis bullosa. <i>Vestnik Dermatologii I Venerologii</i> , 2021, 97, 6-19.	0.6	1
15	Epidemiology and status of specialized medical care for patients with cutaneous T-cell lymphomas: A survey of 163 patients of Russian Federation. <i>Journal of Modern Oncology</i> , 2021, 23, 628-634.	0.3	1
16	Cutaneous lichen amyloidosis within scratched areas. <i>Russian Open Medical Journal</i> , 2018, 7, e0205.	0.3	0
17	Possibility of combined therapy with an oral phosphodiesterase-4 inhibitor (apremilast) and dihydrofolatereductase inhibitor (methotrexate) in patients with psoriatic arthritis plaque psoriasis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 292-298.	0.6	0
18	Phototherapy of mycosis fungoides. <i>Oncogematologiya</i> , 2019, 14, 18-26.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Skin cytokine profile in patients with mycosis fungoides. Vestnik Dermatologii I Venerologii, 2020, 96, 14-19.	0.6	0
20	Melanoma in patients with mycosis fungoides. Vestnik Dermatologii I Venerologii, 2021, 97, 87-95.	0.6	0
21	Resolution of the Working Meeting of Experts in "Dermatology": Possibilities of systemic therapy of atopic dermatitis with selective immunosuppressants. Russian Journal of Allergy, 2022, 19, 259-269.	0.2	0